<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2FC71C0E-FE5A-4A04-B517-35BA155CE1CA"><gtr:id>2FC71C0E-FE5A-4A04-B517-35BA155CE1CA</gtr:id><gtr:name>VarleighDx</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D657B59F-F040-46B5-A35B-D457C06CE596"><gtr:id>D657B59F-F040-46B5-A35B-D457C06CE596</gtr:id><gtr:name>Becton, Dickinson and Company (BD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/590D3D38-1DFA-4131-B82B-1B042C577ABF"><gtr:id>590D3D38-1DFA-4131-B82B-1B042C577ABF</gtr:id><gtr:name>Cytosystems Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/7369E051-ECFC-4808-A044-651879C318D1"><gtr:id>7369E051-ECFC-4808-A044-651879C318D1</gtr:id><gtr:name>MRC Cancer Cell Unit</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB2 2XZ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7369E051-ECFC-4808-A044-651879C318D1"><gtr:id>7369E051-ECFC-4808-A044-651879C318D1</gtr:id><gtr:name>MRC Cancer Cell Unit</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB2 2XZ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2FC71C0E-FE5A-4A04-B517-35BA155CE1CA"><gtr:id>2FC71C0E-FE5A-4A04-B517-35BA155CE1CA</gtr:id><gtr:name>VarleighDx</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D657B59F-F040-46B5-A35B-D457C06CE596"><gtr:id>D657B59F-F040-46B5-A35B-D457C06CE596</gtr:id><gtr:name>Becton, Dickinson and Company (BD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/590D3D38-1DFA-4131-B82B-1B042C577ABF"><gtr:id>590D3D38-1DFA-4131-B82B-1B042C577ABF</gtr:id><gtr:name>Cytosystems Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A5EA518B-306E-4A34-A07A-25F85960D131"><gtr:id>A5EA518B-306E-4A34-A07A-25F85960D131</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Coleman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105359875"><gtr:id>13C7E8CA-C3FC-4F19-A5D9-5AA14F94E416</gtr:id><gtr:title>Translational approaches to improving cancer screening and diagnosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105359875</gtr:grantReference><gtr:abstractText>As we understand more about how tumours arise, it should be possible to devise better strategies to diagnose and treat cancer. We are aiming to develop more effective ways to detect common malignancies, through an understanding of the biology of cancer cells. We are currently analysing a test that we have developed to improve diagnosis of cancers at a number of sites in the body, including cervix, mouth and bowel. For the first two cancers we are working in collaboration with colleagues in Bangalore, India. In addition, we are investigating the mechanisms by which some types of human papillomavirus, the wart virus, cause cancer in the genital tract, particularly the cervix. We are studying the process by which fragments of the virus are inserted into the DNA of infected cells, as well as the significance of changes in the levels of cellular genes that are associated with the development of malignancy. This work may lead to methods to predict how aggressive a particular tumour will be, so that each patient receives neither too little nor too much treatment, and may also suggest new strategies for treating the disease.</gtr:abstractText><gtr:technicalSummary>We aim to: (i) use minichromosome maintenance proteins (MCMs) as biomarkers to improve cancer screening and (ii) study mechanisms of human papillomavirus (HPV)-associated carcinogenesis, in order to develop more effective prognostic and therapeutic interventions for cervical cancer, an epithelial malignancy of major global importance. We demonstrated the clinical value of MCM immunocytochemistry in improving the early detection of several common malignancies, including cervical, colorectal and lung cancer. The first clinical product is now in use internationally and a second generation version is in major FDA trials. We use a unique preclinical model of HPV-related carcinogenesis, validated through a large tissue resource, to study relationships between viral and host factors in the early stages of the cervical metaplasia-dysplasia-carcinoma sequence. As part of this work we discovered the role of two genes that are frequently over-expressed in cervical cancers and will study the potential of one of these, the cytokine receptor OSMR, to act as a cell surface target for antibody-based inhibition. We will further investigate the mechanisms by which HPV oncogene expression is deregulated during cervical carcinogenesis and study the significance of viral physical state (episomal vs. integrated) and site of integration into the host genome, as well as mechanisms of HPV persistence in cervical epithelial cells. We aim to develop new tools for diagnosis and treatment at different stages in the lengthy progression sequence from HPV infection to malignancy. Important clinical benefits of this work will be reduced morbidity and costs associated with over-treatment of non-progressive cervical pre-cancers and improved therapeutic options in cervical carcinomas, particularly early-stage disease.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3790066</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Diego (UCSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>Geeta Mukherjee</gtr:description><gtr:id>9C929B91-A691-4BE9-88C6-092D39753D86</gtr:id><gtr:impact>PubMed ID- 17516585, 17471471, 17342084</gtr:impact><gtr:outcomeId>C7EADB24DCC-1</gtr:outcomeId><gtr:partnerContribution>Exchange of research resources knowledge</gtr:partnerContribution><gtr:piContribution>Exchange of research resources knowledge</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Becton, Dickinson and Company (BD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Beckton Dickinson, Global</gtr:description><gtr:id>AAC84A9B-373A-41A0-8D64-30A7440698A5</gtr:id><gtr:impact>Development of MCM technology for FDA approval.</gtr:impact><gtr:outcomeId>4ED035DDFF1-2</gtr:outcomeId><gtr:partnerContribution>Research discussionsresearch discussions</gtr:partnerContribution><gtr:piContribution>Development of MCM technology for FDA approval.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cytosystems Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of MCM technology for bladder cancer screening</gtr:description><gtr:id>E651C93C-5994-4756-9FFE-0A7DA37DC580</gtr:id><gtr:impact>Development of MCM technology for FDA approval.</gtr:impact><gtr:outcomeId>F6B83CE6ADA-1</gtr:outcomeId><gtr:partnerContribution>Research discussions</gtr:partnerContribution><gtr:piContribution>Research discussions</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>Margaret Stanley</gtr:description><gtr:id>044D19E6-9620-48B2-8B55-FFC3D9D2F9B9</gtr:id><gtr:impact>PubMed ID- 19645010, 19035938, 18652663, 18413654, 17642065, 16973673, 16505361</gtr:impact><gtr:outcomeId>022358CC7AD-1</gtr:outcomeId><gtr:partnerContribution>Exchange of knowledge and research methods</gtr:partnerContribution><gtr:piContribution>Exchange of knowledge and research methods</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Becton, Dickinson and Company (BD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Beckton Dickinson, Global</gtr:description><gtr:id>D2035B17-A0B7-4A38-A739-1E46AE25B644</gtr:id><gtr:impact>Development of MCM technology for FDA approval.</gtr:impact><gtr:outcomeId>4ED035DDFF1-1</gtr:outcomeId><gtr:partnerContribution>Research discussionsresearch discussions</gtr:partnerContribution><gtr:piContribution>Development of MCM technology for FDA approval.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>VarleighDx</gtr:collaboratingOrganisation><gtr:description>VarleighDx</gtr:description><gtr:id>6D0467C4-1718-48E8-A958-90295B901A62</gtr:id><gtr:impact>Launch of a CE-marked test for early diagnosis of pancreatic cancer</gtr:impact><gtr:outcomeId>58c970f78e81d4.55403491-1</gtr:outcomeId><gtr:partnerContribution>Commercialisation of MCM test</gtr:partnerContribution><gtr:piContribution>Launch of a CE-marked test for early diagnosis of pancreatic cancer</gtr:piContribution><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E82EA6B4-1437-4348-9106-9460C5CE14E4</gtr:id><gtr:impact>Spotting cancer quicker in developing countries http://www.mrc.ac.uk/Newspublications/News/MRC003623

Increased profile.</gtr:impact><gtr:outcomeId>07D0A369D75</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E42FF4E8-FE90-4241-BB1D-6CC761759D29</gtr:id><gtr:impact>Cambridge scientists discover an additional step along the road to cervical cancer http://www.mrc.ac.uk/Newspublications/News/MRC002008

Increased profile.</gtr:impact><gtr:outcomeId>3A4FF32F8C9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4D1D8CA0-E463-4280-A7CC-FB835E11895C</gtr:id><gtr:impact>Fighting HPV could help cervical cancer develop http://www.mrc.ac.uk/Newspublications/News/MRC003341

Increased profile.</gtr:impact><gtr:outcomeId>C7FC7469FD5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3432035F-CCF1-42ED-B8BA-FDF1DC2BCBD8</gtr:id><gtr:impact>Press release on MRC website- A new 'smear test' to prevent anal cancer http://www.mrc.ac.uk/Newspublications/News/MRC004911

Increased profile</gtr:impact><gtr:outcomeId>895871E495F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C72C4EC7-6B00-4D50-ACEA-D03C81077BD3</gtr:id><gtr:impact>Cancer screening part of the exhibit involve microscopes to compare Pap and MCM screening.

Increased understanding of cancer screening with MCM proteins.</gtr:impact><gtr:outcomeId>DB1DD199C19</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Showcase Oncology and Tumour Biology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>034AB00E-218E-4A68-A64B-5EF438627BEF</gtr:id><gtr:impact>Lecture entitled: New targets for improving the clinical management of cervical neoplasia.

Increased awareness of the work's clinical potential.</gtr:impact><gtr:outcomeId>BAECD3CB88E</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6C5F961E-9740-430F-A6B9-1F60CC45C402</gtr:id><gtr:impact>Press interest following receipt of Medical Futures Innovation Award. Innovation honour for cancer cell scientists http://www.mrc.ac.uk/NewsViewsAndEvents/News/MRC003798

Widespread press coverage, increasing awareness of the work and its potential.</gtr:impact><gtr:outcomeId>AD9913050F3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7B763017-BA4C-43D7-AF46-5E2707A16E0C</gtr:id><gtr:impact>Press release on screening for oral cancer. http://www.mrc.ac.uk/Newspublications/News/MRC001721

Increased profile.</gtr:impact><gtr:outcomeId>FBCE69CC1A6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Cambridge Press Release - LIN28/let-7 axis in germ cell tumours</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>55B92802-F02A-470B-9D95-4DF9E45CF153</gtr:id><gtr:impact>Interest from media and reported in national press, August 2013

Increased correspondence from patient groups and other health care professionals re the potential for targetting this pathway therapeutically</gtr:impact><gtr:outcomeId>545be366aff6e6.48704254</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.cam.ac.uk/research/news/scientists-discover-a-molecular-switch-in-cancers-of-the-testis-and-ovary</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>99840</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Children with Cancer UK project grant</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Children with Cancer UK</gtr:fundingOrg><gtr:id>60FA7A9B-168E-48F9-B280-5ADB193B01D6</gtr:id><gtr:outcomeId>546380221700a5.11559543</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32611</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Isaac Newton Trust</gtr:department><gtr:description>Assessing the clinical utility of blood-based microRNAs for the management of malignant germ cell tumours</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>34952F43-3E39-4E28-BDE5-3738AD67906C</gtr:id><gtr:outcomeId>56cb0533b26fb7.72892876</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cytosystems Collaborative Project Grant</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Cytosystems Ltd</gtr:fundingOrg><gtr:id>AE1C369D-14C4-4E93-8711-5D18B267C3C1</gtr:id><gtr:outcomeId>4E5AB99300F0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14223</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2008-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>89C613C8-D55B-4343-9131-68FC5E2FC551</gtr:id><gtr:outcomeId>3832D5315A80</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230961</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2485B4B3-2AAD-4882-BEFE-79D6FA2BEC53</gtr:id><gtr:outcomeId>54637c76613bf2.52035194</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>79960</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CLIC Sargent Project Grant</gtr:description><gtr:end>2009-01-02</gtr:end><gtr:fundingOrg>CLIC Sargent</gtr:fundingOrg><gtr:id>8B331244-0CFE-4AE4-8175-DDEF9D7EF28D</gtr:id><gtr:outcomeId>55C40753AE50</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>148000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Children with Cancer UK project grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Children with Cancer UK</gtr:fundingOrg><gtr:id>CB2E1CF8-1A50-4E86-985A-8DD7A0695DB1</gtr:id><gtr:outcomeId>54637fe9c3e240.07568278</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2008-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>0FB9D301-E56E-431E-B18C-E53902291CA6</gtr:id><gtr:outcomeId>4FADFF36B6B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230968</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship - Murray</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B596C467-8C04-4AAC-B92A-2C33BBDCA787</gtr:id><gtr:outcomeId>2CB0854C4F30</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56517</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Addenbrooke's Charity, Project Grant</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>Addenbrooke's Charitable Trust (ACT)</gtr:fundingOrg><gtr:id>5D05E2E8-FA25-413A-854D-6502212A67B6</gtr:id><gtr:outcomeId>EE7E325C7D40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45781</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Addenbrookes Charity, Consumables Grant</gtr:description><gtr:end>2007-01-02</gtr:end><gtr:fundingOrg>Addenbrooke's Charitable Trust (ACT)</gtr:fundingOrg><gtr:id>312CC104-05AD-4D13-8848-401A03079968</gtr:id><gtr:outcomeId>UpzCorDxmsP0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Amgen Studentship scheme</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Amgen Inc</gtr:fundingOrg><gtr:id>DD8BA00F-F32A-4E9E-8C10-2B4456CB5284</gtr:id><gtr:outcomeId>gbBMFbntHSz0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23186</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Institute of Cancer - Kavragiilidou</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>2113565C-BF3F-4FE5-9E70-37DD772EA688</gtr:id><gtr:outcomeId>99309D0E73E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Improving Outcomes for Children and Young Adults with Extracranial Germ Cell Tumours</gtr:description><gtr:end>2021-01-02</gtr:end><gtr:fundingOrg>St. Baldrick's Foundation</gtr:fundingOrg><gtr:fundingRef>RG79925</gtr:fundingRef><gtr:id>6785AECD-B2B5-4049-99E0-C26427790631</gtr:id><gtr:outcomeId>56cb0453dfabe7.34075221</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and precancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.</gtr:description><gtr:grantRef>MC_U105359875</gtr:grantRef><gtr:id>94809795-27BB-4C40-A94E-AB536B19D077</gtr:id><gtr:impact>Licenced to Beckton Dickinson and Cytosystems. Licencing income being received.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>B00D513D980</gtr:outcomeId><gtr:patentId>US2003143646</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Detection of dysplastic or neoplastic cells using anti-MCM2 antibodies</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of Drosha as marker of adverse outcome and as a potential therapeutic target in squamous cell carcinoma.</gtr:description><gtr:grantRef>MC_U105359875</gtr:grantRef><gtr:id>6FFFB1B8-D60C-4913-8EFB-449A7D8E75E7</gtr:id><gtr:impact>Ongoing research into mechanisms underlying the effects of Drosha over-expression.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>24D2AE13A73</gtr:outcomeId><gtr:patentId>WO2008125883</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Cancer Markers for prognosis and screening of anti-cancer agents</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A 3-dimensional substrate for improved packing density in microarrays, and for registering sample deposition.</gtr:description><gtr:grantRef>MC_U105359875</gtr:grantRef><gtr:id>0AF816CC-7CCD-4FEB-964B-2F8A8344629E</gtr:id><gtr:impact>Partnership with MiniFAB Pty Ltd, Victoria, Australia.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5BEF8219959</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Substrate for holding an array of experimental samples</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Experimental Cancer Medicine Centres (ECMC) Steering Group: Standardisation of analysis and reporting of circulating miRNAs by RTqPCR</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>95893B2F-2833-4A8E-A4B0-E7AF5334C49A</gtr:id><gtr:outcomeId>56cc2dbeb7bcb1.41738500</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cancer Research UK Science Plan Review: Biomarkers.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8A44B29B-450E-4698-A901-9629B89C0EBD</gtr:id><gtr:outcomeId>3E0FEACE4E2</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>An MCM-based test for primary cervical screening.</gtr:description><gtr:id>ED7ABEA0-3EA1-4B62-B0CD-FC88A2CBD27A</gtr:id><gtr:impact>Currently on hold.</gtr:impact><gtr:outcomeId>E8B921F7D16</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>SurePathPlus</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>An MCM-based test for early detection of bladder cancer using cytology samples.</gtr:description><gtr:id>00F1EB1E-5F63-4AFF-9D93-42D5C672E1E6</gtr:id><gtr:impact>Still in development by Cytosystems Ltd.</gtr:impact><gtr:outcomeId>9C9DB42B1BE</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Cytosystems solution</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A molecular test for early diagnosis of cervical cancer and pre-cancer in cytology and histology preparations.</gtr:description><gtr:id>709004E4-1661-4F99-AF79-176C994BF22D</gtr:id><gtr:impact>Increasing use in US and elsewhere, both for intended use and off label use.</gtr:impact><gtr:outcomeId>EF181537028</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>ProExC</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Sliding windows adaptive thresholds CGH is an automated array comparative genomic hybridisation analysis software written in R for Linux / Unix and incorporating distributed processing with condor middleware.

Roberts I, Carter SA, Scarpini CG, Karagavriilidou K, Barna JC, Calleja M, Coleman N (2012)
A high throughput computational framework for identifying significant copy number aberrations from array comparative genomic hybridisation data
Advances in Bioinformatics 2012:876976</gtr:description><gtr:id>41E4184E-FF58-4DB3-8BF2-786E83207970</gtr:id><gtr:impact>We have developed an R based strategy to region of interest detection. swatCGH is a BASH wrapper to R and condor camgrid. It automates the process of sending the array data to condor camgrid. It manages the linking to snapCGH for preprocessing, undertaking region analysis with custom functions, and returning the results in a manageable web style format.</gtr:impact><gtr:outcomeId>54638aed800633.02904357</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>swatCGH</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://www.path.cam.ac.uk/research/investigators/coleman/swatCGH/004.html</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Published in BJC in 2016 - details included in manuscript (PMID 26671749)</gtr:description><gtr:id>EFA4863C-B190-430C-A870-4A11FC0FFCA9</gtr:id><gtr:impact>Interest from other national and international research groups to replicate our model/pipeline</gtr:impact><gtr:outcomeId>56cc2e7a6f68e0.15435872</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Pipeline for robust serum microRNA detection/analysis in malignant germ cell tumours</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>With the approval of the Children's Cancer and Leukaemia Group, we obtained the entire UK collection of paediatric malignant germ cell tumours (n=120). We have systematically characterised global changes in genomic DNA, messenger RNA and microRNA levels, and are currently examining relationships between the data sets, in collaboration with bioinformatics colleagues in Cambridge.</gtr:description><gtr:id>DC7E66AC-CCFE-41E7-B80E-E664A244A375</gtr:id><gtr:impact>Improved understanding of the biology of malignant germ cell tumours in children, including the differences that expalin differences in clinical behaviour compared to equivalent tumours in adults.</gtr:impact><gtr:outcomeId>EB2C80E3067</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UK archive of paediatric malignant germ cell tumours</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In collaboration with Kidwai Institute, India and University of Aberdeen, we have obtained a collection of cervical squamous cell carcinomas and squamous intraepithelial lesions (n=~70). We have systematically characterised global changes in genomic DNA, messenger RNA and microRNA levels, and are currently examining relationships between the data sets, in collaboration with bioinformatics colleagues in Cambridge.</gtr:description><gtr:id>65A8EEFE-720F-433E-8BAD-131884886F15</gtr:id><gtr:impact>Improved understanding of the biology of cervical squamous cell neoplasia.</gtr:impact><gtr:outcomeId>F957FEAA152</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Archive of cervical squamous cancers and pre-cancers</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>W12 cell line, a model of cervical carcinogenesis. W12 is a non-clonal cell culture, propagated from a cervical low-grade squamous intraepithelial lesion (LSIL) that arose following natural cervical infection with HPV16, which represents a unique system for studying early events in HPV-associated carcinogenesis. At early passages, Southern blotting reveals approximately 100 human papillomavirus type 16 (HPV16) episomes per cell, with no detectable integrants, and the cells recapitulate an LSIL in organotypic tissue culture. Long term in vitro culture series are characterised by spontaneous clearance of episomes and the emergence of cells containing integrated HPV16, with different integrants being selected in different culture series. These changes are associated with the development of high level genomic instability and phenotypic progression through high-grade SIL to squamous cell carcinoma.</gtr:description><gtr:id>F02262B3-BEF7-4990-8E7C-207053E3A350</gtr:id><gtr:impact>W12 is acknowledged as the only cell line system in the world that accurately models cervical carcinogenesis following natural infection with HPV16.</gtr:impact><gtr:outcomeId>FBDC531493B</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>W12 cell line</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3F9E791E-5E9D-4AAA-B258-8C146B64F1B1</gtr:id><gtr:title>Methylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/028fd847b82ed844018ff4568a3ecf41"><gtr:id>028fd847b82ed844018ff4568a3ecf41</gtr:id><gtr:otherNames>Jeyapalan JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>YbtNUuRpMVQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B92503EA-6134-4D85-8CA2-D44E335381F3</gtr:id><gtr:title>Depletion of polycistronic transcripts using short interfering RNAs: cDNA synthesis method affects levels of non-targeted genes determined by quantitative PCR.</gtr:title><gtr:parentPublicationTitle>Virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b93646eadd98ab3074e0bd2fb059d0b"><gtr:id>4b93646eadd98ab3074e0bd2fb059d0b</gtr:id><gtr:otherNames>Hanning JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1743-422X</gtr:issn><gtr:outcomeId>doi_53cd4dd4d713d693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E7DF61E-71BE-467C-902B-35E233CCA49F</gtr:id><gtr:title>Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4455576d3461d8066e8d04c4b6c2e5d"><gtr:id>f4455576d3461d8066e8d04c4b6c2e5d</gtr:id><gtr:otherNames>Muralidhar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>DfYPzcvSjCj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F162B712-EE9D-4D24-95B9-E0FBB8BF8BFE</gtr:id><gtr:title>Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f69cf9b9a81fb26c178eafda2f64dbbd"><gtr:id>f69cf9b9a81fb26c178eafda2f64dbbd</gtr:id><gtr:otherNames>Hoare M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>616091677BC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90CE66FB-72D4-4903-A730-8B3E6D0C9C95</gtr:id><gtr:title>The two most common histological subtypes of malignant germ cell tumour are distinguished by global microRNA profiles, associated with differential transcription factor expression.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>Mi4Dwtnojp6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB6A6E61-2EF8-4517-AB5B-535A90772B07</gtr:id><gtr:title>Identification of host transcriptional networks showing concentration-dependent regulation by HPV16 E6 and E7 proteins in basal cervical squamous epithelial cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea8d2229b6041178dfdf593795ba27aa"><gtr:id>ea8d2229b6041178dfdf593795ba27aa</gtr:id><gtr:otherNames>Smith SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c5c23990e5e9.58592300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2585887F-6C07-4048-A56E-81EF6A51CCD6</gtr:id><gtr:title>Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR.</gtr:title><gtr:parentPublicationTitle>BMC biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1472-6750</gtr:issn><gtr:outcomeId>EEA44BE59A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41A1AABB-75E3-40B6-B8E7-22C3970379BC</gtr:id><gtr:title>DNA Replication</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800b2ece303172a839274a43cafcbf5a"><gtr:id>800b2ece303172a839274a43cafcbf5a</gtr:id><gtr:otherNames>Jackson A, Laskey RA and Coleman N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54633d838e81a3.69466319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBEDA03D-4E1F-40DB-8EBF-25E57B65E899</gtr:id><gtr:title>Testicular cancer: a new generation of biomarkers for malignant germ cell tumours.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>pm_15897_27_22549310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07667FE2-C92D-49CC-B5D6-E9DB28F981C2</gtr:id><gtr:title>Vacuolation in hepatocyte nuclei is a marker of senescence.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc00046c2d70a092d574b46528d53f3"><gtr:id>6cc00046c2d70a092d574b46528d53f3</gtr:id><gtr:otherNames>Aravinthan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>5463405d04f246.76886263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91FAAAD6-0304-42DD-87F0-BFA8B5473861</gtr:id><gtr:title>Solid tumors of childhood display specific serum microRNA profiles.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>56caff1ecd02e4.34544434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>128CAC34-64A1-4656-AA97-184B41522BAF</gtr:id><gtr:title>Depletion of HPV16 early genes induces autophagy and senescence in a cervical carcinogenesis model, regardless of viral physical state.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b93646eadd98ab3074e0bd2fb059d0b"><gtr:id>4b93646eadd98ab3074e0bd2fb059d0b</gtr:id><gtr:otherNames>Hanning JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_53cd4d7d4d735460b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>933AF36D-23F6-4A47-98BE-3C4F755FA7E6</gtr:id><gtr:title>Solid tumours of childhood display specific serum microRNA profiles</gtr:title><gtr:parentPublicationTitle>VIRCHOWS ARCHIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac5cab70b796d0545ecd113ae9cc8c46"><gtr:id>ac5cab70b796d0545ecd113ae9cc8c46</gtr:id><gtr:otherNames>Murray M. J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0945-6317</gtr:issn><gtr:outcomeId>56cafe2c635630.90622312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46618E1C-BA9D-453A-9B40-5B7D2079079F</gtr:id><gtr:title>Serum levels of mature microRNAs in DICER1-mutated pleuropulmonary blastoma.</gtr:title><gtr:parentPublicationTitle>Oncogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2157-9024</gtr:issn><gtr:outcomeId>pm_15897_27_24513630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46A48BA5-2E65-4092-9A77-AE1775AB8870</gtr:id><gtr:title>The present and future of serum diagnostic tests for testicular germ cell tumours.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>58c5c239172dd5.11029332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35ED14B5-57C6-4919-8DFC-AA287751B6B4</gtr:id><gtr:title>Regulation of human genome expression and RNA splicing by human papillomavirus 16 E2 protein.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c65a151204d8214c76481818f519c66a"><gtr:id>c65a151204d8214c76481818f519c66a</gtr:id><gtr:otherNames>Gauson EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>54633df3d96751.62655299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CDAD5E1-04B3-48AB-85D2-B3A884466C8E</gtr:id><gtr:title>Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis.</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34b440f32bf0710b88cce9a7af1b09d8"><gtr:id>34b440f32bf0710b88cce9a7af1b09d8</gtr:id><gtr:otherNames>Woo YL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn><gtr:outcomeId>F70A03F23A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDE2890C-6A1A-4FDE-8230-2679D98D315E</gtr:id><gtr:title>Lipoprotein lipase is frequently overexpressed or translocated in cervical squamous cell carcinoma and promotes invasiveness through the non-catalytic C terminus.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae31b44d8502b2e7b34448402e9a5717"><gtr:id>ae31b44d8502b2e7b34448402e9a5717</gtr:id><gtr:otherNames>Carter SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_53cd4d6d4d6fe4e32</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D95F62E-29CF-4E3D-95CB-8DA4D0889861</gtr:id><gtr:title>Virus transcript levels and cell growth rates after naturally occurring HPV16 integration events in basal cervical keratinocytes.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdb3cf3bcae9e91fbca4674c1d012e53"><gtr:id>bdb3cf3bcae9e91fbca4674c1d012e53</gtr:id><gtr:otherNames>Scarpini CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_53cd4d7d4d75c59ae</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F831C822-E778-47E9-A099-39ED5E0FE016</gtr:id><gtr:title>Paediatric extracranial germ-cell tumours.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbb5c2a7461c5c796c5b46901c839d5f"><gtr:id>cbb5c2a7461c5c796c5b46901c839d5f</gtr:id><gtr:otherNames>Shaikh F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>58c5c2395798b2.25995613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9866DB80-5101-4BC2-BE46-8D23BDC325BD</gtr:id><gtr:title>Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26f7007614bdad779c5fa7eaed91b3f7"><gtr:id>26f7007614bdad779c5fa7eaed91b3f7</gtr:id><gtr:otherNames>Palmer RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pc7eNMgMMxE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A8FBF9D-8DF1-414A-B68F-C317C46172A9</gtr:id><gtr:title>Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d026370f72b74ec43f01b6fff6911943"><gtr:id>d026370f72b74ec43f01b6fff6911943</gtr:id><gtr:otherNames>Unitt E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>B9A06CE33E9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FEE2B86-3406-4735-84A8-724B5DC86107</gtr:id><gtr:title>Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9faa33f65a55cac3f699714ba5a4741e"><gtr:id>9faa33f65a55cac3f699714ba5a4741e</gtr:id><gtr:otherNames>Kucia-Tran JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58c5c239daa481.45862151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>664704F7-9464-45D1-97FE-B739861B105E</gtr:id><gtr:title>Diagnosis of bladder cancer by immunocytochemical detection of minichromosome maintenance protein-2 in cells retrieved from urine.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/249341a425bb0b60cffdba419c7f92cb"><gtr:id>249341a425bb0b60cffdba419c7f92cb</gtr:id><gtr:otherNames>Saeb-Parsy K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>doi_53cd4dd4d7099c2e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE55EA21-9D87-471C-8F12-10FFDAFAFD90</gtr:id><gtr:title>Virus and Host Events in Squamous Carcinogenesis.</gtr:title><gtr:parentPublicationTitle>The Keio journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1106018db8c2e2c2b93efd438fec4e8c"><gtr:id>1106018db8c2e2c2b93efd438fec4e8c</gtr:id><gtr:otherNames>Coleman N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-9717</gtr:issn><gtr:outcomeId>58c5c23a1f8c38.72321052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC0D2C54-7712-4866-9499-CF9905DDA4C5</gtr:id><gtr:title>LIN28 Expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_540e181e1819ea7c5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>474DF75C-CE44-4115-B942-BA150F894A37</gtr:id><gtr:title>Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7302809953bb0edcba63185d2fac5efc"><gtr:id>7302809953bb0edcba63185d2fac5efc</gtr:id><gtr:otherNames>Isaacson Wechsler E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_53cd4d6d4d6e321b6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3771AA8-BA97-4213-BB5A-216CF436048F</gtr:id><gtr:title>Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5641c3a06f84b645f19bfe261139e8b1"><gtr:id>5641c3a06f84b645f19bfe261139e8b1</gtr:id><gtr:otherNames>Caffarel MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>doi_53cd4dd4d75283c3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>762E7C96-89E8-44C0-B6FB-F6747372C3E2</gtr:id><gtr:title>Biology of childhood germ cell tumours, focussing on the significance of microRNAs.</gtr:title><gtr:parentPublicationTitle>Andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2047-2919</gtr:issn><gtr:outcomeId>54609c6c456214.93258603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15D8A847-F8CC-4828-AD5E-2AEBF7B47DEC</gtr:id><gtr:title>Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/538b6b2857a606b83c6e40227361d780"><gtr:id>538b6b2857a606b83c6e40227361d780</gtr:id><gtr:otherNames>Laurenson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn><gtr:outcomeId>FQwHMEcpnnY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66A6EB4C-4B0F-4326-8432-06DBBD7D7977</gtr:id><gtr:title>Pediatric malignant germ cell tumors show characteristic transcriptome profiles.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26f7007614bdad779c5fa7eaed91b3f7"><gtr:id>26f7007614bdad779c5fa7eaed91b3f7</gtr:id><gtr:otherNames>Palmer RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>BEFF1CCBC08</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A2A108D-B460-485B-8736-1C45DC17178A</gtr:id><gtr:title>Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc722048a54e804889d5682d065c8589"><gtr:id>dc722048a54e804889d5682d065c8589</gtr:id><gtr:otherNames>Marshall AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>oYbDQZeJMzo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11A4B3F5-4657-45A3-9CF9-4485C015E491</gtr:id><gtr:title>Correction: Chronic Hepatitis B Virus Infection: The Relation between Hepatitis B Antigen Expression, Telomere Length, Senescence, Inflammation and Fibrosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25d70be60260dc58aabb0ca0e5619e06"><gtr:id>25d70be60260dc58aabb0ca0e5619e06</gtr:id><gtr:otherNames>Tachtatzis PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c5c23a5ae5f5.11599375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEBC2BCD-3D86-491A-B09F-E7E8C7F9F689</gtr:id><gtr:title>Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/285971162ae020cd94a848c1b5607434"><gtr:id>285971162ae020cd94a848c1b5607434</gtr:id><gtr:otherNames>Winder DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>FtRziXgEKiU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CC76565-9D1F-4627-9031-A44A22C52984</gtr:id><gtr:title>In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6e261b5ce65b87737e7eb4b642351e4"><gtr:id>d6e261b5ce65b87737e7eb4b642351e4</gtr:id><gtr:otherNames>Gray E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>dgBAPT2SJ86</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EAF0A55-220D-4D9F-A4C1-58B3C5A597F6</gtr:id><gtr:title>Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5641c3a06f84b645f19bfe261139e8b1"><gtr:id>5641c3a06f84b645f19bfe261139e8b1</gtr:id><gtr:otherNames>Caffarel MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_53cd4d7d4d729a981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>773B24B3-0A1F-470B-BBAD-6602DF1FEB8E</gtr:id><gtr:title>Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b93646eadd98ab3074e0bd2fb059d0b"><gtr:id>4b93646eadd98ab3074e0bd2fb059d0b</gtr:id><gtr:otherNames>Hanning JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_53cd4d7d4d71f0ab2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EF6B32B-DE93-4A36-BEA1-062C0CB6DDE7</gtr:id><gtr:title>DICER1 hotspot mutations in non-epithelial gonadal tumours.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56d02bb6684d2d790194f9046ab151cf"><gtr:id>56d02bb6684d2d790194f9046ab151cf</gtr:id><gtr:otherNames>Witkowski L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>54634091234552.68374552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D88D5E9D-1893-414E-A342-712A7AC80C1D</gtr:id><gtr:title>Variable methylation of the imprinted gene, SNRPN, supports a relationship between intracranial germ cell tumours and neural stem cells.</gtr:title><gtr:parentPublicationTitle>Journal of neuro-oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e65ad8ad8d99155072e5805168e305c6"><gtr:id>e65ad8ad8d99155072e5805168e305c6</gtr:id><gtr:otherNames>Lee SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0167-594X</gtr:issn><gtr:outcomeId>ozSmYV76bTh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0806909C-E16C-4DC2-B169-0D3EE9CCBB67</gtr:id><gtr:title>Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5728571f039dceb726397ff7a2199a51"><gtr:id>5728571f039dceb726397ff7a2199a51</gtr:id><gtr:otherNames>Scarpini C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>4493D04B0AD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7C45B21-983F-43DC-871D-7EDCB38DE27B</gtr:id><gtr:title>Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcf0418ac54d0e6675f94d467483d81b"><gtr:id>bcf0418ac54d0e6675f94d467483d81b</gtr:id><gtr:otherNames>Gillis AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>pm_15897_27_24012110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>414FBA51-1CBD-43EF-AB93-7096EE36954A</gtr:id><gtr:title>A high-throughput computational framework for identifying significant copy number aberrations from array comparative genomic hybridisation data.</gtr:title><gtr:parentPublicationTitle>Advances in bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1687-8027</gtr:issn><gtr:outcomeId>doi_53cd4dd4d6eed008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDF8F3AE-17E0-4FAB-B35B-FBE9293B0D8B</gtr:id><gtr:title>Identification of microRNAs From the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors.</gtr:title><gtr:parentPublicationTitle>American journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9173</gtr:issn><gtr:outcomeId>fRDGXmy8z8q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0016849C-A39B-4C2B-96C8-BFEFCEA3BC00</gtr:id><gtr:title>FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34b440f32bf0710b88cce9a7af1b09d8"><gtr:id>34b440f32bf0710b88cce9a7af1b09d8</gtr:id><gtr:otherNames>Woo YL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>25E85B4E375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9224F15-3242-40EA-B587-E94E359D34FF</gtr:id><gtr:title>Age-related biological features of germ cell tumors.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6916cd5efb743794447ea2c257e650cb"><gtr:id>6916cd5efb743794447ea2c257e650cb</gtr:id><gtr:otherNames>Collinson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn><gtr:outcomeId>54609bc540c8b6.47068327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64721D45-DC8E-4C5E-84D1-DB7AAA3CD98C</gtr:id><gtr:title>Isolation of stool-derived mucus provides a high yield of colonocytes suitable for early detection of colorectal carcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/098ef4d8f9665826e53407e67a2eb527"><gtr:id>098ef4d8f9665826e53407e67a2eb527</gtr:id><gtr:otherNames>White V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>5ABDF4B5C71</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7555E388-7DA7-4608-80B8-8A80052375F7</gtr:id><gtr:title>Heterogeneous inflammatory changes in liver graft recipients with normal biochemistry.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bb146a1ca2fd6ccdb674915215d79ec"><gtr:id>5bb146a1ca2fd6ccdb674915215d79ec</gtr:id><gtr:otherNames>Gelson W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>jNnv471jp9w</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1B42C50-C08A-453F-B762-31461B6F6BD5</gtr:id><gtr:title>Serum microRNA screening for DICER1-associated pleuropulmonary blastoma.</gtr:title><gtr:parentPublicationTitle>Pediatric blood &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a9eb643892cf6d165a4a027d05161ce"><gtr:id>5a9eb643892cf6d165a4a027d05161ce</gtr:id><gtr:otherNames>Bailey S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1545-5009</gtr:issn><gtr:outcomeId>546098bdadfdf5.90428465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>062086AA-EA0A-4CC1-B0CD-FCCECA9A6BAB</gtr:id><gtr:title>Familial rhabdoid tumour 'avant la lettre'--from pathology review to exome sequencing and back again.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56d02bb6684d2d790194f9046ab151cf"><gtr:id>56d02bb6684d2d790194f9046ab151cf</gtr:id><gtr:otherNames>Witkowski L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5463409147a0d9.64599975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>460CBB2C-5E04-4FB8-BF3E-0E25F8481EDB</gtr:id><gtr:title>Characterization of naturally occurring HPV16 integration sites isolated from cervical keratinocytes under noncompetitive conditions.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a6e07f58d8fbda59f4c702920dfc5b3"><gtr:id>1a6e07f58d8fbda59f4c702920dfc5b3</gtr:id><gtr:otherNames>Dall KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>48DF845D8D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ECABED5-CAD7-45A6-AF32-CE5B3849BB19</gtr:id><gtr:title>Pathogenesis of human papillomavirus-associated mucosal disease.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f06bcf853a3b3f2f7c17989d10224b85"><gtr:id>f06bcf853a3b3f2f7c17989d10224b85</gtr:id><gtr:otherNames>Groves IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>56df04c30832f3.83721679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70718F05-8AAF-49BB-975A-A42AD5458EEA</gtr:id><gtr:title>Minichromosome maintenance proteins in cancer screening.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1106018db8c2e2c2b93efd438fec4e8c"><gtr:id>1106018db8c2e2c2b93efd438fec4e8c</gtr:id><gtr:otherNames>Coleman N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>C0EAA42FBFD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA0AC594-FFA1-4D3E-80A9-61446CE7C807</gtr:id><gtr:title>Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc00046c2d70a092d574b46528d53f3"><gtr:id>6cc00046c2d70a092d574b46528d53f3</gtr:id><gtr:otherNames>Aravinthan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5463405d2faa90.64503821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05260424-1678-422E-9CE7-1291E03CC6BF</gtr:id><gtr:title>A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34b440f32bf0710b88cce9a7af1b09d8"><gtr:id>34b440f32bf0710b88cce9a7af1b09d8</gtr:id><gtr:otherNames>Woo YL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>1D03414335A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5475BF7F-7F61-4D4D-8FE0-C6BBFF02D312</gtr:id><gtr:title>A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98136b98a07f8ae33ef41569cbc66294"><gtr:id>98136b98a07f8ae33ef41569cbc66294</gtr:id><gtr:otherNames>Murray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56cafdfabcebb7.02453632</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105359875</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>